Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
spartalizumab + CJM112
- Development stage
- Discontinued
- Lead developer
- Novartis
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
The combination of **spartalizumab** and **CJM112** comprises two investigational monoclonal antibodies developed by Novartis for immunotherapy. **Spartalizumab** (also known as PDR001) is a humanized IgG4 monoclonal antibody that targets **programmed death-1 (PD-1)**, acting as a checkpoint inhibitor to enhance anti-tumor immune responses. **CJM112** is a human IgG1 monoclonal antibody that binds to **interleukin-17A (IL-17A)** and **interleukin-17AF (IL-17AF)**, neutralizing their pro-inflammatory activity. The combination was studied in early-phase clinical trials for **relapsed and/or refractory multiple myeloma** to determine safety, tolerability, and preliminary anti-tumor activity[1][4][6]. The clinical development was terminated early due to recruitment challenges[1].
- Other names
- spartalizumab + CJM112PDR001 + CJM112
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)IL-17A (Interleukin-17A)IL17F (Interleukin 17F)
Beyond the preview
Go deeper on spartalizumab + CJM112.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on spartalizumab + CJM112.